We report the results of a prospective trial of lirilumab in patients with myelodysplastic syndrome (MDS). A total of 10 patients were included. Higher-risk patients received lirilumab with azacitidine, lower-risk patients received single-agent lirilumab. Two patients achieved complete remission (CR) and 5 achieved marrow CR. Although the small sample size precludes definitive conclusions, the results of this study indicate the efficacy and safety of lirilumab in patients with MDS. Background: Enhancement of natural killer cell activity by blocking interactions between killer immunoglobulin (Ig)-like receptors (KIRs) and human leukocyte antigen-C (HLA-C) molecules can improve outcomes in myeloid malignancies. Lirilumab is a human IgG4 monoclonal antibody that blocks KIR/HLA-C interaction. We designed a study to evaluate the safety and efficacy of lirilumab as a single agent and in combination with azacitidine in patients with myelodysplastic syndrome (MDS). Patients and Methods: Adult patients with MDS who had not received previous hypomethylating agents were included. Lower-risk MDS patients received single-agent lirilumab (3 mg/kg); higher-risk patients received azacitidine (75 mg/m 2 /day for 7 days) in combination with lirilumab (3 mg/kg, on day 7), in a 28-day cycle. Responses were evaluated according to 2006 International Working Group criteria. Results: A total of 10 patients including 8 with higher and 2 with lower-risk enrolled. The median age was 70 (range, 50-84) years and 4 (40%) had complex cytogenetics. Baseline molecular mutations included TP53 (n ¼ 5), TET2 (n ¼ 3), and NRAS (n ¼ 2). Patients received a median of 4 (range, 2-13) and 9 (range, 5-14) cycles of treatment with azacitidine with lirilumab and single-agent lirilumab, respectively. Two patients achieved complete remission (CR), 5 marrow CR, and 3 had stable disease. The median event-free survival for the entire cohort was 8 months (95% confidence interval, 4 months to not reached), and the median overall survival has not yet been reached. Five patients experienced 8 episodes of Grade !3 adverse events attributable to study drug, with the most frequent being infection or neutropenic fever (75%). Conclusion: Lirilumab either as a single agent as well as used in combination with azacitidine has clinical activity in patients with MDS. Further studies are needed to confirm our findings.
Introduction
Myelodysplastic syndrome (MDS) consists of a heterogeneous group of myeloid malignancies characterized by bone marrow failure and increased risk of transformation to acute myelogenous leukemia (AML). 1, 2 The outcome of patients with MDS is very variable with median survival ranging from >5 years to <6 months. 2 At present, allogeneic hematopoietic cell transplantation (HSCT) is the only treatment that can induce long-term remissions. 3, 4 Such therapy, however, is not applicable to most patients, because the median age at diagnosis exceeds 70 years. The standard first-line therapy for most patients with higher risk MDS is a hypomethylating agent (HMA) such as azacitidine or decitabine. 5, 6 Although HMAs have significant activity in MDS and have been shown to improve survival, most patients will either not respond to HMA or will lose their response to therapy. 7, 8 There is an urgent need to develop new therapeutic approaches for patients with MDS. Natural killer (NK) cells are essential components of the innate immune system and play a critical role in host immunity against various malignancies, including leukemias. [9] [10] [11] NK cell function, including cytotoxicity and cytokine release, is governed by a balance between signals received from inhibitory receptors, notably the killer immunoglobulin (Ig)-like receptors (KIRs) and activating receptors. 12 Several groups have reported on the expression of KIR ligands and receptors in myeloid leukemias. [13] [14] [15] Our group recently reported an important influence of activating KIR gene content on progression-free survival in MDS, pointing to a role for NK cells in the immune surveillance of MDS. 16 Lirilumab (IPH2102/BMS-986015) is a fully humanized IgG4 monoclonal antibody that is designed to block the interaction between KIR2DL1/L2/L3 inhibitory receptors and their ligands. By blocking the KIR/human leukocyte-C (HLA-C) interaction, it lowers the threshold for activation of NK cells, without directly activating NK cells. 17 When activated, NK cells release preformed cytotoxic granules into the target cell leading to direct killing of cancer cells. The concurrent release of cytokines and chemokines also results in a microenvironmental milieu that recruits other immune cells.
17,18
The antitumor activity of lirilumab has been shown in xenograft mouse models of solid and hematological malignancies as well as in phase I and pilot phase II clinical trials. [19] [20] [21] We hypothesized that lirilumab, either as a single agent or in combination with azacitidine, could have clinical activity in patients with MDS. Therefore, we designed a pilot phase II study to determine the safety and efficacy of lirilumab alone, or in combination with azacitidine, in patients with MDS.
Patients and Methods
The study was approved by the institutional review board.
Patients
Adult patients with MDS of any risk or chronic myelomonocytic leukemia (CMML), according to the French-AmericanBritish or World Health Organization classification were eligible for this study. The International Prognostic Scoring System (IPSS) 2 
Efficacy and Safety
Patients were evaluated for clinical response with a bone marrow evaluation and complete blood count on day 28 of course 1 (AE3 days) and afterward every 3 months or as indicated to document response or to decide on therapy administration. Response assessment was performed using the revised 2006 International Working Group criteria. 22 Event-free survival (EFS) was defined as the time between the start of therapy and the date of lack of response, loss of response, transformation to AML, or death, whichever occurred first. Overall survival (OS) was defined as the time between the start of therapy and death. Patients who were alive at the last follow-up date were censored in survival analysis. Adverse events (AEs) were graded according to the National Cancer Institute Common Terminology Criteria for Adverse events (version 4.0).
Statistical Considerations
A sample size of 20 patients for each cohort was planned. The efficacy and safety analysis included all subjects who completed !2 cycles of therapy and at least 1 follow-up assessment. Categorical variables were compared using Fisher exact test and continuous variables were compared using 1-way analysis of variance. Survival probabilities were calculated using the KaplaneMeier method.
Results

Patient Characteristics
In total, 10 patients including 8 with higher-risk and 2 with lowerrisk, were enrolled between April 2016 and June 2017 (see Supplemental Table 1 in the online version). Baseline demographic and disease characteristics are summarized in Table 1 . The median age was 70 (range, 50-84) years and 7 patients (70%) were male. Most patients had MDS (n ¼ 9; 90%) and 1 had CMML (10%). Seven patients (70%) had 2 to 3 cytopenias and 5 patients (50%) were transfusion-dependent at enrollment. On chromosomal analysis, 5 patients had diploid karyotype (50%), 4 had complex karyotype (40%), and 1 had del (5q) and del (20q). One patient had received previous therapy for MDS with lenalidomide. All patients had baseline targeted next-generation sequencing (see Supplemental Appendix 1 in the online version). A total of 8 patients (80%) had at least 1 detectable mutation. The most frequently identified mutations included TP53 (n ¼ 5; 50%), TET2 (n ¼ 3; 30%) and NRAS (n ¼ 2; 20%).
Safety
In total 9 patients (90%) experienced at least 1 treatmentemergent AE. Drug-related AEs were reported in all patients in Pilot Trial of Lirilumab With or Without Azacitidine for MDS the higher-risk and in 1 patient in the lower-risk cohort. Five patients (50%) experienced a total of 8 episodes of Grade 3 AEs attributable to study drug, with the most frequent being infection or neutropenic fever (6 of 8; 75%). Frequently reported AEs for both groups are summarized in Table 2 . Treatment-related AEs leading to azacitidine dose reductions occurred in 3 patients (38%). None of the patients discontinued the study treatment because of AEs.
Disease Response
All patients received at least 2 cycles of treatment and were evaluable for response. Response to therapy and outcome in the total study group are shown in Table 3 . The median duration of follow-up was 9.5 months (range, 5-21 months). Higher-risk MDS patients received a median of 4 cycles (range, 2-13 cycles) of treatment with lirilumab in combination with azacitidine, and lower-risk patients received a median of 9 cycles (range, 5-14 cycles) of single-agent lirilumab. Overall, 2 patients (20%) achieved complete remission (CR; n ¼ 2; 25%; higher-risk cohort), 5 patients (50%) had marrow CR (mCR; n ¼ 4; 50%, and n ¼ 1; 50% for the higher-risk and lower-risk cohort, respectively), and 3 patients had stable disease (n ¼ 2; 25%, and n ¼ 1; 50% for the higher-risk and lower-risk cohort, respectively). The median time to best response was 3 months (range, 1-8 months). Additionally, 40% (4 of 10, all of them in the higher-risk cohort) of the patients had hematologic improvement and 40% (2 of 5; 50% for the higher-risk cohort) achieved complete cytogenetic response. Among the 5 patients with TP53 mutations at baseline, 3 were tested for mutation clearance and 1 was found to have clearance of TP53 mutation, after 1 cycle of treatment with azacitidine and lirilumab. Of the patients who were transfusion-dependent at baseline, 40% (2 of 5; 50% of the higher-risk cohort) achieved transfusion independence.
Three of the responding patients in the higher-risk cohort subsequently underwent HSCT. The best responses at the time of transplantation were CR (n ¼ 2) and mCR (n ¼ 1). With a median follow-up of 9 months after HSCT, all of the transplant recipients remained alive and were in CR.
At the time of analysis, 8 patients were removed from the study. In both treatment groups, the most common reason for study discontinuation was progressive disease (n ¼ 4; 40%; among them, 3 progressed to AML and 1 had MDS disease progression), followed by stem cell transplantation (n ¼ 3; 30%). One patient was removed because of myocarditis with no clear etiology. Two patients, 1 from each treatment group, were still receiving study drug at the time of the analysis.
Survival
The median EFS for the entire cohort was 8 months (95% confidence interval, 4 months to not reached), and the median OS has not yet been reached. At 1 year, 70% (n ¼ 7) of the patients were alive. In total, 3 deaths (30%) occurred during follow-up. All of the deaths occurred >30 days after the last treatment during the study and none of them were attributed to protocol therapy. The most common reason for death was disease progression.
Discussion
To the best of our knowledge, the current study is the first clinical trial using lirilumab in patients with MDS. This study indicates that lirilumab either as a single agent or with azacitidine has clinical activity in patients with MDS. Overall, the CR þ mCR rate in this study was 70% and the median OS has not been reached. The treatment was generally tolerated but was associated with relatively high rates of fever and infections that required supportive care.
Although available standard of care therapies like azacitidine have shown an ability to improve the outcomes of patients with MDS, 5, 6, 23 only a subset of patients respond to these treatments, and prognosis remains poor for patients in whom treatment has failed or have had disease relapse. 7, 24 Therefore, there is a need for new therapies in MDS. Natural killer cells constitutively express inhibitory KIRs that bind to HLA class I molecules and prevent NK cell activation toward healthy autologous cells. Evidence in support of NK cell involvement in the antitumor response is derived from the hematopoietic cell transplant setting. In patients who underwent T cell-depleted haploidentical cell transplantation, a KIR ligandmismatched donor favored NK-cell alloreactivity and was associated with improved relapse-free survival. 25, 26 In addition, we recently reported an important role for NK cells and the activating KIR gene content in the immune surveillance of MDS. 16 On the basis of these concepts, disrupting KIR-ligand interaction as a means to prevent inhibitory signaling in NK cells to augment the NK cell effect has been a topic of ongoing investigation. Lirilumab is an anti-KIR antibody that was developed for the treatment of patients with hematologic and solid tumor malignancies. It has been tested in patients with AML who are in CR but ineligible for HSCT 20 and subsequently, in the salvage setting in combination with azacitidine. 21 A randomized phase II study confirmed the safety of lirilumab in such patients; however, the study failed to show an improvement of relapse-free survival, the primary end point. 27 Ongoing clinical trials involving lirilumab mainly focus on identifying synergistic combinations particularly with immune checkpoint inhibitors, such as nivolumab and ipilimumab.
Initially, a sample size of 20 patients for each cohort (higher vs. lower risk) was planned, but the enrollment was stopped after the sponsor's decision not to pursue development of lirilumab for myeloid malignancies. There were no safety issues leading to this decision. In the present study, 8 patients with higher-risk MDS received treatment with lirilumab in combination with azacitidine. Of these, 6 patients (75%) had objective response with 2 achieving complete cytogenetic response. Importantly, half of the patients in our study had TP53 mutation, which has been shown to have a negative effect on outcomes in patients with MDS. [28] [29] [30] We also note that 3 of these patients proceeded to HSCT. HSCT remains the only currently available curative approach for patients with higher-risk MDS. 3, 4 However, outcomes depend on the tumor burden at the time of HSCT and patients with minimal disease at the time of HSCT have better long-term outcomes. 31 Therefore, the azacitidine/lirilumab combination could also serve as a bridge to potentially curative HSCT in eligible patients. Of the lower-risk patients included in our study, 1 patient achieved mCR and continued with the study drug. The other patient had stable disease and had disease progression after 5 cycles of lirilumab therapy. Notably, that patient also had TP53 mutation.
It is important to mention that the present study is small, and that comparisons with studies of single-agent azacitidine are not possible. The results of the current study are encouraging but need to be verified in larger studies.
Conclusion
The results of this study indicate the efficacy and safety of lirilumab in patients with MDS, especially in combination with azacitidine. Although the small sample size precludes definitive conclusions, these findings also indicate that the combination of NK checkpoint blockade with lirilumab and azacitidine might be useful as a bridge to HSCT in eligible patients.
Clinical Practice Points
Natural killer cells are essential components of the innate immune system and play a critical role in host immunity against various malignancies. Natural killer cell function is governed by a balance between signals received from inhibitory receptors, notably the KIRs and activating receptors. Blockage of KIR receptors with a fully human monoclonal antibody is known to enhance NK-mediated lysis of tumor cells. Lirilumab is a fully humanized IgG4 monoclonal antibody that is designed to block the interaction between KIR2DL1/L2/L3 inhibitory receptors and their ligands. To our knowledge, this is the first report of efficacy and safety of the anti-KIR lirilumab in patients with MDS. Our findings indicate that lirilumab is effective and well tolerated either as a single agent or in combination with azacitidine, in patients with MDS in the limited population studied. On the basis of these data, further evaluation of lirilumab in patients with MDS is warranted.
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